Amanda Stahnke1, Kelly Struemph2, Erin Behnen3, Julia Schimmelpfennig4. 1. Clinical Assistant Professor, University of Missouri-Kansas City School of Pharmacy , Kansas City, Missouri. 2. Clinical Pharmacy Lead, Menorah Medical Center , Overland Park, Kansas. 3. Associate Professor, Southern Illinois University Edwardsville School of Pharmacy , Edwardsville, Illinois. 4. Pharmacy Manager - Clinical Services , PGY-1 Residency Program Director, St. Elizabeth's Hospital, Belleville, Illinois .
Abstract
PURPOSE: To develop and implement a protocol to improve blood glucose (BG) control during transition from intravenous (IV) to subcutaneous (SC) insulin, increase compliance with Surgical Care Improvement Project (SCIP) measures, and decrease sternal wound infections post open heart surgery (OHS). METHODS: An IV to SC protocol was developed and implemented. A retrospective chart review of patients who underwent OHS was conducted from January 2, 2009 to September 30, 2010 (pre protocol) and from October 1, 2010 to December 31, 2011 (post protocol). Data collected included age, sex, history of diabetes mellitus (DM), BG values, hypoglycemia incidence, length of stay, and incidence of sternal wound infections. RESULTS: A total of 243 patients were included in the study. Compliance with SCIP postoperative day 1 and 2 BG goals was similar pre and post protocol (P = .24 and .248). One sternal wound infection occurred after protocol implementation, whereas 6 occurred pre protocol (P = .046). Change in BG when transitioning from IV to SC insulin was similar between the groups, however there were significantly fewer hypoglycemia episodes post protocol (P < .001). CONCLUSION: Though differences were not found in compliance with SCIP postoperative day 1 and 2 measures, fewer sternal wound infections and hypoglycemic episodes were reported, indicating that the pharmacy protocol may have a positive impact on patient outcomes.
PURPOSE: To develop and implement a protocol to improve blood glucose (BG) control during transition from intravenous (IV) to subcutaneous (SC) insulin, increase compliance with Surgical Care Improvement Project (SCIP) measures, and decrease sternal wound infections post open heart surgery (OHS). METHODS: An IV to SC protocol was developed and implemented. A retrospective chart review of patients who underwent OHS was conducted from January 2, 2009 to September 30, 2010 (pre protocol) and from October 1, 2010 to December 31, 2011 (post protocol). Data collected included age, sex, history of diabetes mellitus (DM), BG values, hypoglycemia incidence, length of stay, and incidence of sternal wound infections. RESULTS: A total of 243 patients were included in the study. Compliance with SCIP postoperative day 1 and 2 BG goals was similar pre and post protocol (P = .24 and .248). One sternal wound infection occurred after protocol implementation, whereas 6 occurred pre protocol (P = .046). Change in BG when transitioning from IV to SC insulin was similar between the groups, however there were significantly fewer hypoglycemia episodes post protocol (P < .001). CONCLUSION: Though differences were not found in compliance with SCIP postoperative day 1 and 2 measures, fewer sternal wound infections and hypoglycemic episodes were reported, indicating that the pharmacy protocol may have a positive impact on patient outcomes.
Authors: Etie S Moghissi; Mary T Korytkowski; Monica DiNardo; Daniel Einhorn; Richard Hellman; Irl B Hirsch; Silvio E Inzucchi; Faramarz Ismail-Beigi; M Sue Kirkman; Guillermo E Umpierrez Journal: Endocr Pract Date: 2009 May-Jun Impact factor: 3.443
Authors: Harold L Lazar; Marie McDonnell; Stuart R Chipkin; Anthony P Furnary; Richard M Engelman; Archana R Sadhu; Charles R Bridges; Constance K Haan; Rolf Svedjeholm; Heinrich Taegtmeyer; Richard J Shemin Journal: Ann Thorac Surg Date: 2009-02 Impact factor: 4.330
Authors: Laurie Warrington; Phil Ayers; Anna Marie Baldwin; Virginia Wallace; Krista D Riche; Robert Saulters; Oliver Grey Waldrop; Teri Dyess; Gordon Bart Delashmet; Samuel Peeples; W Stewart Horsley; William J Harris; Kenneth Butler Journal: Am J Health Syst Pharm Date: 2012-07-15 Impact factor: 2.637